a public good project by the
Synthesis
Company
of California

© 2026

Andrzej Maćkiewicz | doi.page

0 works0 citations0 h-index

Andrzej Maćkiewicz

Poznan University of Medical Sciences(PL)Częstochowa University of Technology(PL)Greater Poland Cancer Center(PL)NASK National Research Institute(PL)

Publications by Year

Research Areas

Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Gut microbiota and health, Melanoma and MAPK Pathways

Most-Cited Works

→ Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib(2014)2,623 cited
→ Principal components analysis (PCA)(1993)1,530 cited
→ Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma(2019)1,339 cited
→ The soluble interleukin‐6 receptor is generated by shedding(1993)509 cited
→ Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance(2021)490 cited
→ Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial(2017)487 cited

→ Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins(1992)

375 cited

→ Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial(2021)373 cited

Acute Phase Proteins Molecular Biology, Biochemistry, and Clinical Applications(1993)

→ Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial(2015)257 cited